High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle-stimulating hormone, and testosterone in normal men

被引:44
作者
Behre, HM
Kliesch, S
Puhse, G
Reissmann, T
Nieschlag, E
机构
[1] UNIV MUNSTER, INST REPROD MED, WHO, COLLABORATING CTR RES HUMAN REPROD, D-48129 MUNSTER, GERMANY
[2] ASTA MED, FRANKFURT, GERMANY
关键词
D O I
10.1210/jc.82.5.1403
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The GnRH antagonist cetrorelix effectively suppresses serum LH, FSH, and testosterone (T) in normal men without major side-effects. However, as with other available GnRH antagonists, relatively high doses of 10 mg/day were required for sustained reduction of T levels during 1-week administration in normal men. Therefore, we investigated whether a suppression of LH, FSH, and T achieved by initial high dose cetrorelix can be maintained by continued low dose injections. Sixteen young male volunteers were randomly assigned to four study groups (n = 4/group). Twelve men were injected sc with 10 mg cetrorelix at 0800 h for 5 days, followed by injections of 2 mg/day (group I), 2 x 1 mg/day (group II), and 1 mg/day (group III) up to the end of the 3-week injection period. For the control, group IV was given daily placebo injections for 3 weeks. Morning and evening blood samples were obtained daily for 4 weeks and then at increasing time intervals up to meek 13. Initial injections of 10 mg/day cetrorelix suppressed LH, FSH, and T effectively. This initial reduction of serum levels was maintained during the following low dose maintenance injections in all groups. In comparison to the initial suppression, significantly lower levels of LH, FSH, and T near the assay detection limits were measured during study weeks 2 and 3. The results show that compared to previous long term studies, much lower daily doses of the GnRH antagonist are sufficient for effective suppression of LH, FSH, and T after initial high loading dose injections. In addition to competitive receptor blockage, other mechanisms of GnRH antagonist action, such as receptor down-regulation, appear to be involved during long term administration in men.
引用
收藏
页码:1403 / 1408
页数:6
相关论文
共 18 条
[1]   COMPARISON OF A GONADOTROPIN-RELEASING-HORMONE ANTAGONIST PLUS TESTOSTERONE (T) VERSUS-T ALONE AS POTENTIAL MALE CONTRACEPTIVE REGIMENS [J].
BAGATELL, CJ ;
MATSUMOTO, AM ;
CHRISTENSEN, RB ;
RIVIER, JE ;
BREMNER, WJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (02) :427-432
[2]  
BAJUSZ S, 1988, INT J PEPT PROT RES, V32, P425
[3]   DEPOT GONADOTROPIN-RELEASING-HORMONE AGONIST BLUNTS THE ANDROGEN-INDUCED SUPPRESSION OF SPERMATOGENESIS IN A CLINICAL-TRIAL OF MALE CONTRACEPTION [J].
BEHRE, HM ;
NASHAN, D ;
HUBERT, W ;
NIESCHLAG, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (01) :84-90
[4]   EFFECTIVE SUPPRESSION OF LUTEINIZING-HORMONE AND TESTOSTERONE BY SINGLE DOSES OF THE NEW GONADOTROPIN-RELEASING-HORMONE ANTAGONIST CETRORELIX (SB-75) IN NORMAL MEN [J].
BEHRE, HM ;
KLEIN, B ;
STEINMEYER, E ;
MCGREGOR, GP ;
VOIGT, K ;
NIESCHLAG, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (02) :393-398
[5]   SUSTAINED SUPPRESSION OF SERUM LH, FSH AND TESTOSTERONE AND INCREASE OF HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL BY DAILY INJECTIONS OF THE GNRH ANTAGONIST CETRORELIX OVER 8 DAYS IN NORMAL MEN [J].
BEHRE, HM ;
BOCKERS, A ;
SCHLINGHEIDER, A ;
NIESCHLAG, E .
CLINICAL ENDOCRINOLOGY, 1994, 40 (02) :241-248
[6]  
BEHRE HM, 1995, EXP CLIN ENDOCR S, V103, P141
[7]  
BEHRE HM, 1995, P 77 ANN M END SOC
[8]  
Conn P M, 1995, Vitam Horm, V50, P151, DOI 10.1016/S0083-6729(08)60656-1
[9]  
Engel J, 1996, TREATMENT WITH GNRH ANALOGS: CONTROVERSIES AND PERSPECTIVES, P69
[10]  
FILICORI M, 1996, TREATMENT GNRH ANALO